Efficacy and Safety of Three Times a Day BIAsp-70 Compared to Two Times a Day BIAsp-30 in Subjects With Type 2 Diabetes

Trial to Investigate the Efficacy and the Safety of Thrice-Daily NN2000-Mix70 (NovoRapid 70 Mix) Compared to Twice-Daily NN-X14Mix30 (NovoRapid 30 Mix) in Subjects With Type 2 Diabetes Mellitus

This trial is conducted in Japan. This a clinical trial to study the efficacy and safety of three times a day BIAsp-70 compared to two times a day BIAsp-30 in subjects with type 2 diabetes.

Inclusion Criteria:

• Subjects with type 2 diabetes
• Current treatment using intermediate-acting, long-acting insulin (including long-acting insulin analogue) or pre-mixed human insulin for at least 24 weeks
• HbA1c at least 7.5% and below 10.0%

Exclusion Criteria:

• Proliferative retinopathy or maculopathy requiring acute treatment
• Impaired hepatic and/or renal function
• Cardiac diseases
• Uncontrolled hypertension
• Known hypoglycemia unawareness or recurrent major hypoglycemia